CLBX Share Price Performance
UK£0.01
-0.11 (-91.28%)
89.8% undervalued intrinsic discount
UK£0.10
Fair Value
Price UK£0.01
AnalystHighTarget UK£0.10
AnalystConsensusTarget UK£0.07
AnalystLowTarget UK£0.04
Fair ValueUK£0.10
Share Pricen/a
CelLBxHealth plc Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
CLBX Community Narratives
AN
Fair Value UK£0.1 89.8% undervalued intrinsic discount
Global Aging And Liquid Biopsy Will Redefine Early Cancer Detection
0users have liked this narrative
1users have commented on this narrative
1users have followed this narrative
AN
Fair Value UK£0.07 85.4% undervalued intrinsic discount
Leadership Appointment And Diagnostic Partnerships Will Shape Future Market Expansion
1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value UK£0.04 74.4% undervalued intrinsic discount
Regulatory Scrutiny And Binary Deals Will Hinder Precision Medicine
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Leadership Appointment And Diagnostic Partnerships Will Shape Future Market Expansion
Key Takeaways ANGLE's unique technologies and partnerships in precision oncology position it for strong, margin-expanding revenue growth as liquid biopsy adoption accelerates. Ongoing innovation, clinical validation, and disciplined cost management enhance ANGLE's competitive strength, diversify revenues, and improve long-term profitability.Read more
86
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
UK£0.07
85.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
106.5% p.a.
Profit Margin
11.3%
Future PE
11.12x
Price in 2029
UK£0.09
Global Aging And Liquid Biopsy Will Redefine Early Cancer Detection
Key Takeaways Rapid scaling of major partnerships and NHS integration could significantly boost contract conversion, recurring revenue, and visibility beyond current expectations. Unique technology positions ANGLE for industry leadership, with direct patient testing and clinical lab accreditation driving premium pricing, market share, and high-margin service expansion.Read more
49
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
1users have followed this narrative
AN
UK£0.1
89.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
47.83% p.a.
Profit Margin
10.89%
Future PE
45.15x
Price in 2029
UK£0.13
Regulatory Scrutiny And Binary Deals Will Hinder Precision Medicine
Key Takeaways Regulatory hurdles and deal timing uncertainty create risks for revenue growth and may lead to irregular or delayed earnings progression despite industry momentum. Heavy reliance on core technology and tight research funding environment expose the company to innovation risk and constrain diversification and profitability improvements.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
UK£0.04
74.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
47.11% p.a.
Profit Margin
7.86%
Future PE
25.45x
Price in 2029
UK£0.05
Trending Discussion
Recently Updated Narratives
AN
CLBX: Equity Raises And Lower Risk Profile Will Support Oncology Upside
Fair Value: UK£0.07 85.4% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CLBX: Future Repricing Will Rely On Equity Raises And Margin Expansion
Fair Value: UK£0.1 89.8% undervalued intrinsic discount
1 followerusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
CLBX: Equity Raises And QIAGEN Alliance Will Support Future Upside Potential
Fair Value: UK£0.04 74.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CelLBxHealth plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.014
- 31.36%
- -601.37%
- 0%
About CLBX
- Founded
- 1994
- Employees
- 119
- CEO
- WebsiteView website
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.
